FULCRUM THERAPEUTICS INC has a total of 37 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Chile. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are SHANGHAI CHUANG HONG BIOTECHNOLOGY CO LTD, INST CANCER RES D B A THE RES INST OF FOX CHASE CANCER CT and ATOSSA GENETICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Chile | 3 | |
#4 | Australia | 2 | |
#5 | Brazil | 2 | |
#6 | Canada | 2 | |
#7 | China | 2 | |
#8 | Colombia | 2 | |
#9 | EPO (European Patent Office) | 2 | |
#10 | Israel | 2 | |
#11 | Republic of Korea | 2 | |
#12 | Philippines | 2 | |
#13 | Taiwan | 2 | |
#14 | Ecuador | 1 | |
#15 | New Zealand | 1 | |
#16 | Singapore | 1 | |
#17 | Uruguay | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Measuring microorganism processes | |
#4 | Microorganisms | |
#5 | Peptides | |
#6 | Enzymes | |
#7 | Analysing materials | |
#8 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Wallace Owen Brendan | 32 |
#2 | Cacace Angela Marie | 29 |
#3 | Rojas Soto Luis Gustavo Alejandro | 29 |
#4 | Chang Aaron Nakwon | 26 |
#5 | Robertson Alan Scott | 26 |
#6 | Shen Ning | 26 |
#7 | Ronco Lucienne V | 24 |
#8 | Thompson Lorin A Iii | 14 |
#9 | Thompson Lorin A | 9 |
#10 | Thompson Iii Lorin A | 8 |
Publication | Filing date | Title |
---|---|---|
WO2020190754A1 | Macrocyclic azolopyridine derivatives as eed and prc2 modulators | |
WO2020106876A2 | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease | |
US2019105311A1 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
BR112020006677A2 | use of p38 inhibitors to reduce dux4 expression | |
WO2018170290A1 | Compositions and methods for increasing fmr1 expression |